neurological · Mechanism Report
Can anti-Ri antibodies signal cancer-related neurologic autoimmunity after breast cancer?
Confirmed anti-Ri antibodies can signal cancer-associated neurologic autoimmunity and support assessment for active or recurrent cancer when clinically appropriate.
This is what AI claimed
Anti-Ri antibodies in a patient with prior breast cancer can be a paraneoplastic neurologic immune signal and warrant assessment for active or recurrent malignancy when clinically appropriate.
Executive summary
Anti-Ri antibodies are strongly associated with cancer and may occur alongside cerebellar or brainstem symptoms. They recognize neuronal proteins that may also be expressed by tumors, but a positive result alone does not establish a paraneoplastic neurologic syndrome.
Verified conclusion
Anti-Ri (ANNA-2) antibodies are a high-risk paraneoplastic neurologic marker. In a person with prior breast cancer—particularly with a compatible subacute cerebellar or brainstem syndrome—the finding supports concern for tumor-associated neurologic autoimmunity and clinically appropriate investigation for occult, active, or recurrent cancer.
Clinical evidence
- Anti-Ri has a cancer association exceeding 70%. In a review of 85 reported anti-Ri paraneoplastic syndrome cases, cancer was identified in 73 (85.9%); breast cancer accounted for 63% of identified tumors. Earlier cohorts reported malignancy in approximately 86–92%.
- Associations are sex- and context-dependent: breast cancer is especially important in women, while lung cancer is a notable association in men.
- Relevant neurologic presentations include subacute cerebellar/brainstem dysfunction, ataxia, and opsoclonus-myoclonus. Neurologic symptoms may precede cancer detection or occur after an established cancer diagnosis.
Mechanistic and diagnostic interpretation
- Anti-Ri recognizes intracellular neuronal RNA-binding proteins NOVA1 and NOVA2. Tumor expression of neuronal antigens provides a plausible basis for immune cross-recognition of tumor and nervous-system targets, with evidence implicating both T-cell and humoral immune responses.
- A positive result supports but does not independently establish paraneoplastic neurologic syndrome. Interpretation requires a compatible phenotype, reliable antibody confirmation, and cancer correlation. Isolated serum or low-titer commercial line-blot results warrant confirmation with tissue-based testing and an antigen-specific assay.
Clinical implications
- Cancer assessment should be directed by phenotype, sex, age, and history. Breast-focused imaging may be particularly relevant after prior breast cancer; FDG-PET/CT can be considered when conventional studies are unrevealing.
- If initial evaluation is negative but clinical suspicion remains high, PNS-Care supports repeat screening every 4–6 months for 2 years, individualized to risk and course.
Bottom line
- Confirmed anti-Ri in this context is a meaningful paraneoplastic immune signal and supports targeted—sometimes repeated—assessment for active or recurrent malignancy, particularly breast cancer.
References
- Breast Cancer Specificities of Patients With Anti-Ri Paraneoplastic Neurologic Syndromes — neurology.org
- T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation — ncbi.nlm.nih.gov
- Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes — air.uniud.it
- Clinical features of paraneoplastic neurologic syndromes with ... — pmc.ncbi.nlm.nih.gov
- Clinical spectrum and diagnostic pitfalls of neurologic syndromes with Ri antibodies | Neurology Neuroimmunology & Neuroinflammation — neurology.org
- Anti-neuronal nuclear autoantibody type 2: paraneoplastic accompaniments. — europepmc.org
- Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force — pmc.ncbi.nlm.nih.gov
See a full patient report verified like this
Book a walkthrough